



Streptomyces-Derived Nano-Doxorubicin: Clinical Status and Patents Granted

Prabhjot Kaur,¹ Divya Dhawal Bhandari,² Hitesh Chopra³

Abstract

Streptomyces have been presented as a great source of antibiotics and anti-cancer drugs over the past century. Especially *Streptomyces* living in adverse conditions produce certain metabolites with cytolytic and anti-microbial activities, which have been utilised for manufacturing antimicrobial and anticancer drugs. Doxorubicin (DOX) is a potent anti-cancer drug derived from *Streptomyces*, that is widely used for various cancers, including cancers of the ovary, urinary bladder, GI tract, breast, thyroid gland, lung, bone, kidney (nephroblastoma) and blood (leukaemia). This anthracycline antibiotic is limited by its adverse effect profile, with the main adverse effects being nausea, vomiting, alopecia, infertility, cardiotoxicity, myelosuppression and nephrotoxicity. Nanoparticle delivery systems present a good solution to avoid adverse effects. Some nano-based formulations have reached the clinics, while many new ones in the pipeline show promising results. This review attempts to compile the existing literature on the clinical status of DOX highlight the need for the development of nanoparticles (NPs) that may serve as drug delivery agents, imaging probes and other multifunctional particulates. The integration of nanotechnology with *Streptomyces*-derived compounds can help shape the anti-cancer therapy of the future.

Key words: Doxorubicin; Nanostructures; *Streptomyces*; Nanoparticles; Microbial.

1. Chandigarh College of Pharmacy, Landran, Mohali, India.
2. University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.
3. Department of Biosciences, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, India.

Citation:

Kaur P, Bhandari DD, Chopra H. *Streptomyces*-derived nano-doxorubicin: clinical status and patents granted. Scr Med. 2024 Nov-Dec;55(6):775-86.

Corresponding author:

HITESH CHOPRA
E: chopraontheride@gmail.com

Received: 15 July 2024
Revision received: 28 August 2024
Accepted: 29 August 2024

Introduction

When it comes to producing antibiotics, *Streptomyces* is a very significant group of bacteria. These can be found in a variety of habitats ranging from the deep ocean to the highest mountains.^{1, 2} *Actinobacteria* is a phylum of Gram-positive, filamentous, spore-forming bacteria. *Streptomyces* and *Kitasatospora* split around 382 million years ago during the late Devonian era, at the same time when terrestrial animals appeared.^{3, 4} To spread, *Streptomyces* produces hyphae, which are threadlike

filaments that burrow through surfaces in quest of nutrition. Strains such as *Streptomyces* are capable of surviving in adverse settings and dispersing quickly, making them ideal for places with limited resources.^{5, 6}

These secondary metabolites are produced by *Streptomyces* during this development phase and may provide the organism with an edge over its competitors.⁷ These metabolites benefit the vegetative bacteria cells by producing

antibiotics and siderophores and possessing the property to impart coloration (to protect them from UV radiation) and communication with other species. As a result of their relatively big genome, *Streptomyces* are capable of producing a wide range of molecular variations.

Bioactive chemicals produced by *Streptomyces* are well recognised.⁸ Among naturally occurring antibiotics and medicinally important compounds, almost 75 % of these compounds were derived from *Streptomyces*.⁹ All kinds of bioactive secondary metabolites, including those used in human health and agriculture, are reliable sources of microorganisms that attract the interests of scientists.¹⁰ As a result, finding new strains of *Streptomyces* is an urgent and critical task.

Selective media formulations, such as those formulated to promote *Streptomyces* colonies while decreasing other bacteria, have been used to isolate this bacterium from soil. One *Streptomyces* selective media is Benedict's modified Lindenbein medium in which oil suspension is pretreated with extract of yeast and sodium dodecyl phosphate. After pretreatment, oil suspensions undergo heat shock when combined with humic acid vitamin agar, such as *Staphylococcus stifleri*.¹¹ *Streptomyces* numbers increase when soil solution is treated with 1.5 % phenol (30 °C for 30 min). This denatures proteins or destroys cell membranes of common actinomycetes such as bacteria and fungus.¹² This manuscript provides deep understanding about the mechanism of anthracyclines, with particular reference to doxorubicin (DOX) and its nano-formulations for the treatment of cancer.

Anthracyclines

Anticancer medications developed from *Streptomyces* bacteria are anthracyclines. Their antitumour efficacy was shown in the 1960s and they entered clinical usage in

the 1970s. Anthracyclines are red aromatic polyketides that exist in many forms owing to structural variations in the aglycone base molecule and the various sugar residues attached. These medications are not specific to the cell cycle.

Early chemotherapeutic drugs in this family included daunorubicin and DOX. When physicians discovered that cancers gained resistance to those medications whose side effects, such as cardiotoxicity have restricted the dosage of patients that they could tolerate, the medicinal chemists attempted to create adaptations of these compounds - analogues with broader action and lower toxicity. Over the years, more than 2,000 analogues have been researched in an attempt to identify better anthracyclines.¹³ However, only a few of anthracycline analogues, such as epirubicin and idarubicin,¹⁴ have been authorised for clinical use. Cardiac toxicity continues to be a significant issue while taking anthracyclines. Anthracyclines are known to cause damage to DNA by several different processes, some of which include the creation of free radicals, the development of DNA-anthracycline adducts and the poisoning of topoisomerase-II. Anthracycline's semiquinone radical can intercalate between DNA base pairs, which can lead to DNA damage through the formation of reactive oxygen species (ROS).

Mechanism of action

Research on the exact method by which anthracycline functions in the body is still ongoing. However, it is recognised that the main target of popular anthracyclines like DOX is DNA. The basic mechanism involves planar tetracyclic chromophores intercalating between base pairs of DNA, which affects DNA transcription and translation. The cytotoxic activity of anthracyclines is not just dependent on the drug's affinity for binding DNA; other factors, including as the anthracycline's binding mechanism and location, also play a major role in cytotoxicity.

Each anthracycline has a different specificity, binding affinity and binding mechanism based on the DNA base sequence. Daunomycin binds more readily when two GC base pairs have AT between them, that is, GCAT-GC, according to structural, computational and solution-based analyses of the daunomycin-DNA complex.^{15, 16} DNAase foot-printing

and equilibrium binding were used to examine daunorubicin's sequence and site specificity. These experiments show that daunomycin is specific to specific DNA sequences and that as the quantity of GC increases, so does its affinity for binding DNA.¹⁷ Furthermore, to assess daunorubicin's sequence-specific binding, the effect of the restriction endonucleases EcoRI and PvuI on the cleavage of linear pBR322 DNA was examined.¹⁷ EcoRI's and PvuI's recognition sequences are 5'-GAATTC-3' and 5'-CGATCG-3', respectively. PvuI inhibits pBR322 DNA digestion more quickly than EcoRI, as demonstrated by Chaires et al, suggesting that daunorubicin has preferred sequence specificity. Analyses of the crystal structure of daunomycin-DNA d (CpGpTpApCpG) complexes yielded comparable findings.¹⁶ The selectivity for the GC base pair results from the formation of hydrogen bonds upon contact. The hydroxyl group on daunorubicin's C9 forms two hydrogen bonds with guanine's N2 and N3. This predilection for GC base pairs also explains why the drug's binding affinity increases as the GC content of DNA increases. Similar to DOX, epirubicin and idarubicin, the crystal structures of the anthracycline's DOX, epirubicin and idarubicin reveal a sequence-specific intercalative binding mechanism between DNA bases.

In addition, a number of studies were conducted to investigate the DNA intercalation mechanism of anthracyclines. Also created was a spectrofluorometric technique for estimating anthracycline intercalation in live cells and DNA solutions.¹⁸ Using flow cytometry, Belloc et al¹⁹ measured the intercalation of anthracyclines in the DNA of live cells. Using picogreen (a fluorescent dye binding DNA), Ashley et al²⁰ have proven the intercalative capability of anthracyclines in both nuclear and mitochondrial DNA. Mitochondrial toxicity is significantly affected by the intercalation of anthracycline into DNA of mitochondria. As a result of DOX's interaction with DNA, AFM investigations support the likely mechanism of intercalative binding mode.²⁰

Mechanism of resistance

In addition to cardiotoxicity, therapy with anthracyclines induces anthracycline resistance even at the optimum cumulative dosage.²¹ Natural and acquired medication resistance is both possible. Some cells exhibit natural re-

sistance even before the medication is administered; while the acquired one arises with medication intake. Drug resistance is caused by a number of processes, such as changes in the drug's ATP-binding cassette-related efflux and accumulation, qualitative and quantitative changes in topoisomerase II, p53 activity, overexpression of enzymes that scavenge reactive oxygen species, etc. One of the main causes of anthracycline antibiotic resistance is thought to be ABC (ATP-binding cassette) transporter proteins [R]. One of the ABC proteins, P-glycoprotein (Pgp), is considered to cause anthracycline resistance through drug efflux, inflow suppression and drug accumulation within the cell.²² The interaction between anthracycline and Pgp is linked to the active efflux of anthracycline through the cell's transmembrane domain. The *mdr1* gene, which codes for Pgp, is triggered by any chemical or environmental stimuli during cell differentiation. When the anthracycline comes into contact with the plasma membrane and exports it, Pgp recognises it. Therefore, the rising amount of Pgp produces an export-import imbalance.

Moreover, a change in topoisomerase II activity, either quantitatively, ie, a drop in the amount of enzyme, or qualitatively, ie, a change in the normal activity of enzyme owing to mutation or another cause, might confer resistance to the cell against additional doses of anthracyclines. The expression of p53 is required for anthracycline-mediated cell death. Consequently, inactivation or downregulation of p53 might result in drug resistance.²² SOD, GSH and catalase are ROS scavengers and their overexpression during cytotoxicity may also confer anthracycline resistance.²² Increased DNA repair also leads to anthracycline resistance in cells.

Doxorubicin

DOX (ATC code L01DB01) is an antibiotic having chemotherapeutic characteristics and is therefore used in cancer treatment.²³ It originated from the mutant strain of *S peucetius* spp *Caesius* ATCC 27952. *Farmitalia Carlo ErbaSpA* patented the medicine in 1971, with the European Medicines Agency (EMA) and the FDA approving various

products. DOX is one of the most effective anti-tumour anthracycline antibiotics frequently used to treat a variety of cancer types. Due to DOX's high toxicity, its application in medicine is limited [median fatal dosage - $LD_{50} = 21,800$ g/kg (rat, subcutaneous)]. DOX is strongly emetogenic, so anti-emetogenic medications must be prescribed; some patients also report delayed nausea.²⁴ It is also a vesicant, meaning that extravasation from the blood vessel produces significant tissue damage through necrosis, resulting in intense pain.

DOX is mutagenic and possibly carcinogenic in animals and humans. DOX is designated as FDA/pregnancy category D because it may cause gonadal suppression, resulting in amenorrhea or azoospermia, which may lead to infertility. Evidence of human foetal risk is associated with DOX based on adverse reactions, marketing experience, or human studies; however, the benefits of using DOX in pregnant women may often outweigh the risk, although breastfeeding should be avoided during chemotherapy. DOX also alters the male reproductive profile due to testicular injury and a considerable reduction in testicular weight. The damage to cell membranes, DNA and proteins is the result of two different mechanisms performed by DOX:

- (i) Intercalation into DNA, leading to disruption of the DNA repair mechanism intervened by topoisomerase II and
- (ii) Release of free radicals.

The unstable metabolite semiquinone is regenerated from DOX. The pathway of generating reactive oxygen species by DOX can result in oxidative stress, DNA damage, lipid peroxidation, membrane damage and cell death by persuading apoptotic pathways (Figure 1).

Cardiotoxicity has been found to be the most severe toxicity while using anthracyclines^{25, 26} manifesting as either immediate or delayed consequences. Acute left ventricular failure is uncommon, although it may occur, especially in individuals who received more than the maximum recommended dosage of 550 mg/m². Due to the danger of irreparable heart damage, routine monitoring tests must be performed and in the event of suspected cardiotoxicity, the benefit must be considered. Concurrent administration of many medicines such as trastuzumab, paclitaxel – PTX, docetaxel and even radiation raises the menace of cardiotoxicity.²⁷

Patients taking DOX-based chemotherapy often have myelosuppression,²⁸ notably of leukocytes, necessitating haematological function monitoring. DOX is a powerful immuno-suppressant; hence precautions must be taken to prevent secondary infections. Additionally, stomatitis and mucositis often emerge at the start of therapy.^{29, 30} In extreme instances, it may manifest into mucous ulcers in a matter of days. DOX is mostly eliminated by the hepatobiliary system, hence




Figure 1: Mechanism of action of doxorubicin for its anticancer activity

should not be taken by the patients suffering with severe hepatic insufficiency.

DOX treatment is associated with an increase in plasma aspartate transaminase, alanine aminotransferase³¹ and bilirubin levels. Focal hepatocyte destruction, vascular injury and steatosis may also occur. Some individuals who received DOX had lung complications such as pulmonary fibrosis, bronchospasm and local oedema, however, the underlying mechanisms are unknown. It also exhibits nephrotoxic action, as shown by severe congestion, intertubular haemorrhage with damaged epithelium and substantial degenerative alterations,³² resulting in advanced renal damage which indicates that DOX induces chronic nephropathy that leads to end-stage renal failure.

In an effort to maintain DOX's broad-spectrum anticancer efficacy while minimising its toxicity, nanotechnology has been the primary focus. To put it simply, a nanomedicine is a system with nanocarriers and active moieties that may be utilised to treat or diagnose illness. No excipients are present and the nanomedicine exhibits improved bioavailability and drug distribution at the site of action with decreased toxicity.³³ Current chemotherapeutic methods have considerable drawbacks in comparison to nanomedicine. Drug release may be controlled in tumours using a well-designed nanoparticle technology. The increased permeability and retention (EPR) impact of nanoparticles (NPs) of suitable size (200 nm) and surface characteristics may allow them to passively target tumour tissues.³⁴ By shielding its payload medications from enzymes and the harsh physiological environment, NP formulations improve therapeutic effectiveness. There have been significant advances in the development of nanoparticles (NPs) that may serve as drug delivery agents, imaging probes and other multifunctional particulates. Several nano-delivery techniques, including polymeric, organic, inorganic, metallic and lipidic nano-formulations, have been used to lessen the adverse effects of medication delivery. Multiple imaging and targeted drug delivery modalities may be combined into a single particle for concurrent imaging and the treatment of tumour tissues. Using nontoxic, biocompatible and biodegradable polymeric nano-formulations for DOX is a potential strategy to deliver the drug at the desired location while also improving effectiveness and reducing adverse

effects.³⁵ They have prolonged circulatory half-lives, increased permeability and EPR impact along with lower hepatic uptake.³⁶

The mononuclear phagocyte system may identify traditional liposomes (Lip) after their systemic injection followed by prompt removal through reticuloendothelial system.³⁷ This is a key drawback of traditional liposomes. Proteins adsorption and formation of corona are often associated with the identification of Lip, along with other nanocarriers by the immune system followed by their removal from the systemic circulation. The technique that has been utilised most prevalently for minimising protein binding is the coating with inert biocompatible polymers, such as polyethylene glycol (PEG) on the surface of Lip to achieve the so-called 'stealth' surfaces.³⁸ Likewise, it has been proven that including Zwitter ionic lipids in Lip, alike PEGylation, permits decline in binding of proteins further enhancing the duration of plasma retention.³⁹ Moreover, a key issue confronting drug delivery method for treating cancer is the liposomal trigger at the tumour spot.³⁸ In this context, Lip may be built to limit or reduce the discharge of drug in the circulation and normal tissues and release their content only after receiving a precise trigger stimulus at the tumour location, yielding maximum anticancer effects.³⁷

A normal pH value for biological fluids is between 7.4 and 7.6. Tumours have an external pH of 6.5–7.2, while their internal endosomes (5.5–5.0) and lysosomes (4.0–4.5) have even lower pH values.^{40, 41} For this reason, pH-sensitive Lips have been created as delivery systems for anticancer drugs as they have good endosomal membrane fusing capacity, thereby releasing the medication into the cell's cells.^{37, 38} When the Lip components have acid-base ionisable groups or acid-cleavable bonds, the pH sensitivity may be achieved. To add insult to injury, tumours are known to be hyperthermic because of their fast metabolic rate. Cancer cells are more sensitive than healthy ones to temperature fluctuations, which has inspired the creation of Lip nanocarriers that are thermo-responsive and can deliver anticancer therapies.^{37, 42} It has been shown that phospholipids with a gel-to-liquid crystal phase transition at a few degrees above physiological temperature can be used to create a lip that is responsive to temperature changes,⁴³ as demonstrated by 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC).

When treating breast cancer, fat layers in the mammary glands assist to accumulate medication into the breast tissue by oral delivery or direct injection of drug into the fat layers of the breast tissue. Researchers decided to use anionic SAIL [Ch][Ol] because of this consideration.⁴⁴ Oleic acid, a component of [Ch][Ol], has been shown to improve penetrability and absorption in breast fat layers.^{45,46} Literature describes some SAILs including the studies about their aggregation behaviour.^{47,48} Cholinium fatty acid-based ILs were investigated by Tanner et al for transdermal medication delivery.⁴⁹ For the non-invasive administration of insulin, the same IL was tested.⁵⁰ L-glutamic acid and L-alanine's solubility was improved by using [Ch][Ol].⁵¹ Among all choline carboxylate ILs, [Ch][Ol] is the least hazardous, with greater permeability through the fat layers of the breast and improved aggregation behaviour.⁵² The [Ch][Ol] micelles and surface-active characteristics have already been studied.⁵³ Because of the hydrophobic interactions between the oleate ions' carbon chains, [Ch][Ol] may self-aggregate to form nano-sized micelles. Zeta potential measurements from the infrared show the self-assembled structure as anionic one. An external additive, like GA, reduces electrostatic repulsions among head groups, increasing packing and transforming nano-sized micelles into vesicles (SANS data shown in the infra).⁵⁴ Intermolecular H-bonds with choline oleate result in the formation of densely packed aggregated structures at neutral pH when GA stays in its Zwitterionic state, which is composed of both COO and NH₃⁺ ions. Because of its anticancer action,^{55,56} pH sensitivity and propensity of improving the system's permeability, GA was selected above all other amino acids. Biocompatible and pH-responsive, the system might be the greatest drug delivery technology for delivering medications without impacting their effectiveness *via* localised and targeted drug administration. Since both [Ch][Ol] and GA have been shown to increase drug permeation to target cells in the mammary fat layer or by topical application, it is reasonable to assume that this two-scaffold system would work well for administering chemotherapy drugs to target cells in the mammary fat layer or to cells on the skin. Vesicles loaded with DOX were also analysed at acidic and neutral pH. The system displayed the release of 94 % of drug during 16 h at neutral pH compared to 95 % of drug release within 1 h at acidic pH, which indicates a sustained release of

drug at neutral pH. Additionally, the DOX-loaded vesicle system is more cytotoxic to MCF-7 cell lines as compared to free DOX.

It is widely accepted that carbon-based nano-materials, such as graphene oxide (GO), are among the most sophisticated carriers for the effective delivery of medicines and biomolecules. Biocompatibility, large surface area, cheap cost and high drug loading capacity are only some of the advantages of using GO as a drug carrier.⁵⁷ Functional groups such as hydroxyl, epoxy and carboxyl may be found in GO.⁵⁸ It is known that GO nanosheets may be loaded with pharmaceuticals more efficiently *via* van de Waals forces and by using the p-conjugated structure of GO. Even yet, the existence of sharp edges in GO makes it unsuitable for drug delivery since it may disrupt normal cells and aggregate on cell membranes, resulting in toxicity.⁵⁹ Nanoparticles that are functionalised with biocompatible polymers, such as GO nanoparticles, to minimise cytotoxicity, boost solution solubility and maintain their stability under physiological circumstances are often used to address these constraints. Their biodegradability, low toxicity and biocompatibility make polysaccharide nanoparticles ideal drug delivery carriers. Polymers functionalised onto GO sheets include gum Arabic, gelatine, chitosan, starch, glycogen polyethylene glycol, cellulose, poly-caprolactone, polyvinylpyrrolidone and polylactic acid. GL-GA-GO tri-nanocomposite for DOX loading was developed in work as a unique green biocompatible nontoxic material.⁶⁰ Good biocompatibilities, nano size stability and high DOX loading were all shown in the newly developed tri-nanocomposite. The release of DOX from the loaded composite was pH-dependent, in a way of higher release rate at malignant pH as compared to physiological pH. Both the WI-38 and the A549 cells were unaffected by the prepared unloaded tri-nanocomposite. Nanocomposite loaded with DOX was shown to be more effective against A549 cells than conventional DOX, with IC₅₀ values of 51.9 and 86.6 g/mL, respectively. For WI-38 cells, the DOX-loaded composite was less hazardous than conventional DOX, bearing IC₅₀ values of 1.08 and 0.46 µg of DOX/mL, respectively.

Hernandes et al studied the effects of iron-oxide magnetic nanoparticles coupled with the anti-cancer medication DOX on human breast cancer cells *in vitro*. The findings of study demonstrat-

ed that magnetic nanoparticles containing DOX (NpMag+Dox) contribute to the development of a cellular redox imbalance in MCF-7 cells. Additionally, researchers demonstrate that iron-oxide nanoparticles that have been functionalised with DOX generate oxidative stress, which may be observed in the form of DNA damage, lipid peroxidation, disruption of the cell membrane and loss of mitochondrial potential values. Because of this, NpMag+Dox causes MCF-7 cells to pause the cell cycle and reduce the amount of cell migration that occurs. A better delivery of DOX to MCF cells was produced by the association of NpMg+Dox, primarily in the presence of a magnetic field. This resulted in an increase in the death of MCF cells, which ultimately led to a reduction in the toxicity of the therapy for healthy cells, resulting in a more effective treatment.⁶¹

An innovative radio-bioconjugate has been developed for targeted therapy of cancers that overexpress HER2 receptors.⁶² This multimodal treatment combines a potent chemotherapeutic agent (DOX), a β-emitter (¹⁹⁸Au) and a guiding vector (trastuzumab, Tmab). The integration of these components allows for a more precise and effective approach to treating cancer. In order to accomplish this objective, 30 nm radioactive gold nanoparticles (¹⁹⁸AuNPs) were synthesised and then coated with a poly-ethylene glycol (PEG)

linker. This linker was conjugated to DOX and monoclonal antibody (Tmab) through peptide bond formation. Through *in vitro* experiments, it was observed that the radio-bioconjugate showed a strong binding to HER2 receptors and was efficiently taken up by the cells. Using the MTS assay, researchers observed a notable decrease in the viability of SKOV-3 cells in cytotoxicity experiments. After 48 h of treatment with 2.5 MBq/mL, a synergistic cytotoxic effect was observed as a result of the simultaneous presence of DOX and ¹⁹⁸Au. Flow cytometry analysis revealed that DOX-¹⁹⁸AuNPs-Tmab predominantly caused cell cycle arrest in the G2/M phase and late apoptosis. In spheroid models, the radio-bioconjugate demonstrated dose-dependent additive and synergistic effects. *Ex vivo* biodistribution experiments were conducted in mice with SKOV-3 tumours to study the distribution of ¹⁹⁸AuNPs-DOX and DOX-¹⁹⁸AuNPs-Tmab after intravenous and intertumoral administration. Finally, the *in vivo* therapeutic efficacy studies on the same animal model revealed highly encouraging results. They demonstrated a remarkable halt in tumour growth for up to 28 days after a single intertumoral injection of 10 MBq. Hence, the suggested multimodal radio-bioconjugate exhibits immense promise for the targeted therapy of HER2+ cancers.⁶²

Patents related to nano-doxorubicin in cancer treatment

The patents related to Nano-Dox has been tabulated in Table 1.

Table 1: Patents related to nano-doxorubicin in cancer treatment

Patent No	Details of patent	Ref
CN-117085147-B	A biological medicine-related carbon-based drug delivery system loaded with doxorubicin and its manufacture and use were disclosed in the invention. First, carbonising poloxamer, 3-hydroxytyrosol, ferrous ammonium sulphate hexahydrate, 1,3, 5-trimethylbenzene and ammonia water to obtain black nano particles CDF; then, sequentially reacting the black nano particles CDF with ammonia water, tetraethyl silicate, 3-methacryloxypropyl trimethoxy silane, mercaptopropionic acid, dimethyl maleic anhydride, hydrazine hydrate, dialdehyde polyethylene glycol and ace. Dispersing the carbon-based nanomaterial and doxorubicin in water and stirring at room temperature in a dark environment to load the nanomaterial with the medication. The acid-responsive drug delivery mechanism protected against cardiotoxicity caused by doxorubicin compared to tumour-released doxorubicin.	63

RU-2808909-C1	Invention described a method of treating connective tissue sarcoma M-1 in rats using a conjugate of dipropoxybacteriopurpurin with doxorubicin, which included photodynamic therapy and chemotherapy, administered intravenously and laser-exposed to the tumour node during a drug-light interval.	64
CN-115444810-B	Poly(lactic-co-glycolic) acid (PLGA) and lecithin are weighed and dissolved in methylene dichloride to be used as an oil phase, an internal water phase was added and probe ultrasound was performed under the ice water bath to obtain colostrum; transferring the colostrum into Tween-80 solution, ultrasonic treatment to obtain compound emulsion and reduced pressure distillation to remove dichloromethane to obtain DOX-NPs suspension and centrifugation. The doxorubicin-loaded nanoparticle composite temperature-sensitive gel is easy to prepare and has biodegradability, slow-release performance and higher bioavailability.	65
RU-2794798-C1	Patent included doxorubicin in phospholipid nanoparticles with AS ₁₄₁₁ aptamer conjugated with DSPE-PEG ₂₀₀₀ -Mal for targeted tumour administration of a cytostatic drug and a method for generating the composition. In one embodiment, the pharmaceutical composition comprised phospholipids, doxorubicin and AS ₁₄₁₁ aptamer coupled with DSPE-PEG ₂₀₀₀ .	66, 67
CN-114209824-B	The invention described doxorubicin prodrugs that were designed to be used in combination with photo-thermal tumour penetration enhancement and chemotherapy. The improved intertumoral permeation and combination photothermal and chemotherapeutic properties of the nano-medicament made according to the invention make it more effective against tumour cells. The drug accomplished the goal of combining photo-thermal and chemotherapy by using an intelligent size regulation strategy, having a large-size enhanced long circulation in blood, disintegrating into small-size DOX-photothermal conversion nano-particles in a tumour to improve penetration and then generating heat under near infrared light to release DOX once the nano-particles have penetrated the deepest part of the tumour.	68

Conclusion and future directions

Nature already has a vast variety of natural molecules that have a large variety of biological activities,⁶⁹⁻⁷⁴ but due to their poor physical properties, they are not able to permeate or perform their activity to optimum, as a result, nanotechnology-based approaches are used. However, nanotechnology uses various approaches for synthesis or preparation and these are somewhat complex.⁷⁵⁻⁷⁹ Organic and inorganic nanoparticles of varying formulation and fabrication procedures that achieve controllable size, shape and high versatility, have been the subject of numerous recent papers evaluating their relative merits. They contain multiple chemotherapeutic and active molecules and are functionalised for targeted therapy. Despite promising outcomes in preclinical research, only a small fraction of those findings is being put into practice in hospitals. Some nanomedicines

are already in clinical use. First, using smart strategies in cancer nanomedicines for the stratification of patients, various protocols to look for the microenvironment of the tumour and identification of suitable individuals to be included in clinical trials by imaging-based tumour accumulation, was proposed by Van der Meel and colleagues.⁸⁰ Secondly, designing vigilant rational pharmacological combined regimens would amplify the pharmacodynamic and/or pharmacokinetic benefits. They proposed to use tactful approaches for designing modular (pro)drug and drug-delivery systems and library screening to increase the likelihood of formulations developed and experimented in a preclinical setting. The application, translation and use of nanomedicine will all benefit from these astute methods.

Ethics

This study was a secondary analysis based on the currently existing data and did not directly involve with human participants or experimental animals. Therefore, the ethics approval was not required in this paper.

Acknowledgement

Authors would like to thank Panjab University, RIMT University and Saveetha Institute of Medical and Technical Sciences for providing access to literature.

Conflicts of interest

The authors declare that there is no conflict of interest.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Data access

The data that support the findings of this study are available from the corresponding author upon reasonable individual request.

Author ORCID numbers

Prabhjot Kaur (PK):
0000-0002-9781-6668
Divya Dhawal Bhandari (DDB):
0000-0002-2813-0267
Hitesh Chopra (HC):
0000-0001-8867-7603

Author contributions

Conceptualisation: HC
Methodology: HC, DDB
Data curation: DDB, PK
Writing - original draft: HC, DDB
Writing - review and editing: PK

References

1. Waksman SA, Schatz A, Reynolds DM. Production of antibiotic substances by actinomycetes. *Ann N Y Acad Sci.* 2010 Dec;1213:112-24. doi: 10.1111/j.1749-6632.2010.05861.x.
2. Sarmiento-Vizcaíno A, Espadas J, Martín J, Brana AF, Reyes F, García LA, et al. Atmospheric precipitations, hailstone and rainwater, as a novel source of streptomycetes producing bioactive natural products. *Front Microbiol.* 2018 Apr; 9. doi: 10.3389/fmicb.2018.00773.
3. Cunha BR, Fonseca LP, Calado CRC. Antibiotic discovery: Where have we come from, where do we go? *Antibiotics.* 2019 Apr; 8:45. doi: 10.3390/antibiotics8020045.
4. Chater KF. Streptomyces inside-out: A new perspective on the bacteria that provide us with antibiotics. *Philos Trans R Soc Lond B Biol Sci.* 2006 Feb; 361:761-8. doi: 10.1098/rstb.2005.1758.
5. McDonald BR, Curriea CR. Lateral gene transfer dynamics in the ancient bacterial genus *Streptomyces*. *MBio.* 2017 Jun; 8. doi: 10.3390/genes13081402.
6. Chater KF. Recent advances in understanding streptomycetes. *F1000Res.* 2016 Nov; 5:2795. doi: 10.12688/f1000research.9534.1.
7. Bansal H, Singla RK, Behzad S, Chopra H, Grewal AS, Shen B. Unleashing the potential of microbial natural products in drug discovery: focusing on streptomycetes as antimicrobials goldmine. *Curr Top Med Chem.* 2021 Sep; 21:2374-2396. doi: 10.2174/1568026621666210916170110.
8. Kekuda TRP, Onkarappa R, Jayanna N. Characterization and antibacterial activity of a glycoside antibiotic from streptomycetes *variabilis* PO-178. *Sci. Technol. Arts Res J.* 2014 Dec; 3:116-21. doi: 10.4314/star.v3i4.17.
9. Sathya A, Vijayabharathi R, Srinivas V, Gopalakrishnan S. Plant growth-promoting actinobacteria on chickpea seed mineral density: an upcoming complementary tool for sustainable biofortification strategy. *3 Biotech.* 2016 Jun; 6:138. doi: 10.1007/s13205-016-0458-y.
10. Watve MG, Tickoo R, Jog MM, Bhole BD. How many antibiotics are produced by the genus *Streptomyces*? *Arch Microbiol.* 2001 Nov; 176:386-90. doi: 10.1007/s002030100345.
11. Singh V, Haque S, Singh H, Verma J, Vinbha K, Singh R, et al. Isolation, screening and identification of novel isolates of actinomycetes from India for antimicrobial applications. *Front Microbiol.* 2016 Dec; 7. doi: https://doi.org/10.3389/fmicb.2016.01921.

12. Hayakawa M, Sadakata T, Kajiura T, Nonomura H. New methods for the highly selective isolation of Micromonospora and Microbispora from soil. *J Ferment Bioeng.* 1991; 72:320-6. doi: 10.1016/0922-338X(91)90080-Z.
13. Minnotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. *Pharmacol Rev.* 2004 Jun; 56:185-229. doi: 10.1124/pr.56.2.6.
14. McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline chemotherapy and cardiotoxicity. *Cardiovas Drugs Ther.* 2017 Feb; 31:63-75. doi: 10.1007/s10557-016-6711-0.
15. Chaires JB. Biophysical chemistry of the daunomycin-DNA interaction. *Biophys Chem.* 1990 Apr; 35:191-202. doi: 10.1016/0301-4622(90)80008-u.
16. Wang AH, Ughetto G, Quigley GJ, Rich A. Interactions between an Anthracycline Antibiotic and DNA: Molecular Structure of Daunomycin Complexed to d(CpGpTpApCpG) at 1.2-Å Resolution. *Biochem.* 1987 Feb; 26:1152-63. doi: 10.1021/bi00378a025.
17. Chaires JB, Fox KR, Herrera JE, Britt M, Waring MJ. Site and sequence specificity of the daunomycin-DNA Interaction. *Biochem.* 1987 Dec; 26:2227-36. doi: 10.1021/bi00399a031.
18. Tarasiuk J, Frezard F, Garnier-Suillerot A, Gattegno L. Anthracycline incorporation in human lymphocytes. Kinetics of uptake and nuclear concentration. *Biochim Biophys Acta.* 1989 Sep; 1013:1009-17. doi: 10.1016/0167-4889(89)90038-4.
19. Belloc F, Lacombe F, Dumain P, Lopez F, Bernard P, Boisseau MR, Reifers J. Intercalation of anthracyclines into living cell DNA analyzed by flow cytometry. *Cytometry.* 1992;13(8):880-5. doi: 10.1002/cyto.990130811.
20. Ashley N, Poulton J. Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs. *Biochem Biophys Res Commun.* 2009 Jan; 378:450-5. doi: 10.1016/j.bbrc.2008.11.059.
21. Kaye S, Merry S. Tumour cell resistance to anthracyclines--a review. *Cancer Chemother Pharmacol.* 1985;14(2):96-103. doi: 10.1007/BF00434344.
22. Lam V, McPherson JP, Salmena L, Lees J, Chu W, Sexsmith E, et al. p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin. *Leuk Res.* 1999 Oct;23(10):871-80. doi: 10.1016/s0145-2126(99)00102-2.
23. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijs HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. *J Mol Cell Cardiol.* 2012 Jun;52(6):1213-25. doi: 10.1016/j.yjmcc.2012.03.006.
24. Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. *Cancer Invest.* 2001;19(4):424-36. doi: 10.1081/cnv-100103136.
25. Rivankar S. An overview of doxorubicin formulations in cancer therapy. *J Cancer Res Ther.* 2014 Oct-Dec;10(4):853-8. doi: 10.4103/0973-1482.139267.
26. Kim SH, Kim KJ, Kim JH, Kwak JH, Song H, Cho JY, et al. Comparison of doxorubicin-induced cardiotoxicity in the ICR mice of different sources. *Lab Anim Res.* 2017 Jun;33(2):165-170. doi: 10.5625/lar.2017.33.2.165.
27. Volkova M, Russell R 3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. *Curr Cardiol Rev.* 2011 Nov;7(4):214-20. doi:10.2174/157340311799960645.
28. Bhingne KN, Gupta V, Hosain SB, Satyanarayanajois SD, Meyer SA, Blaylock B, et al. The opposite effects of doxorubicin on bone marrow stem cells versus breast cancer stem cells depend on glucosylceramide synthase. *Int J Biochem Cell Biol.* 2012 Nov;44(11):1770-8. doi: 10.1016/j.biocel.2012.06.010.
29. Naidu MU, Ramana GV, Rani PU, Mohan IK, Suman A, Roy P. Chemotherapy-induced and/or radiation therapy-induced oral mucositis--complicating the treatment of cancer. *Neoplasia.* 2004 Sep-Oct;6(5):423-31. doi: 10.1593/neo.04169.
30. Kwon Y. Mechanism-based management for mucositis: option for treating side effects without compromising the efficacy of cancer therapy. *Onco Targets Ther.* 2016 Apr 5;9:2007-16. doi: 10.2147/OTT.S96899.
31. Zhao X, Zhang J, Tong N, Chen Y, Luo Y. Protective effects of berberine on doxorubicin-induced hepatotoxicity in mice. *Biol Pharm Bull.* 2012;35(5):796-800. doi: 10.1248/bpb.35.796.
32. Afsar T, Razak S, Almajwal A, Al-Disi D. Doxorubicin-induced alterations in kidney functioning, oxidative stress, DNA damage and renal tissue morphology; Improvement by Acacia hydaspica tannin-rich ethyl acetate fraction. *Saudi J Biol Sci.* 2020 Sep;27(9):2251-60. doi: 10.1016/j.sjbs.2020.07.011.
33. Liu Y, Miyoshi H, Nakamura M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. *Int J Cancer.* 2007 Jun 15;120(12):2527-37. doi: 10.1002/ijc.22709.
34. Peer D, Karp J, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. *Nature Nanotech.* 2007;2,751-60. doi: 10.1038/nnano.2007.387.
35. Manivasagan P, Bharathiraja S, Bui NQ, Jang B, Oh YO, Lim IG, et al. Doxorubicin-loaded fucoidan capped gold nanoparticles for drug delivery and photoacoustic imaging. *Int J Biol Macromol.* 2016 Oct;91:578-88. doi: 10.1016/j.ijbiomac.2016.06.007.
36. Masood F. Polymeric nanoparticles for targeted drug delivery system for cancer therapy. *Mater Sci Eng C Mater Biol Appl.* 2016 Mar;60:569-78. doi: 10.1016/j.msec.2015.11.067.
37. Aghdam AM, Bagheri R, Mosafer J, Baradaran B, Hashemzadeh M, Baghbanzadeh A, et al. Recent advances on thermosensitive and pH-sensitive liposomes employed in controlled release. *J Control Release.* 2019 Dec 10;315:1-22. doi: 10.1016/j.jconrel.2019.09.018.
38. Franco MS, Gomes ER, Roque MC, Oliveira MC. Triggered drug release from liposomes: exploiting the outer and inner tumor environment. *Front Oncol.* 2021 Mar 16;11:623760. doi: 10.3389/fonc.2021.623760.
39. Montizaan D, Yang K, Reker-Smit C, Salvati A. Comparison of the uptake mechanisms of zwitterionic and negatively charged liposomes by HeLa cells. *Nanomedicine.* 2020 Nov;30:102300. doi: 10.1016/j.nano.2020.102300.
40. Boedtker E, Pedersen SF. The acidic tumor microenvironment as a driver of cancer. *Annu Rev Physiol.* 2020 Feb 10;82:103-26. doi: 10.1146/annurev-physiol-021119-034627.
41. Torres J, Dhas N, Longhi M, García MC. Overcoming biological barriers with block copolymers-based self-assembled nanocarriers. Recent advances in delivery of anticancer therapeutics. *Front Pharmacol.* 2020 Nov 30;11:593197. doi: 10.3389/fphar.2020.593197.

42. García MC, Naitlho N, Calderón-Montañó JM, Drago E, Rueda M, Longhi M, et al. Cholesterol levels affect the performance of aunps-decorated thermo-sensitive liposomes as nanocarriers for controlled doxorubicin delivery. *Pharmaceutics*. 2021 Jun 27;13(7):973. doi: 10.3390/pharmaceutics13070973.
43. Park SM, Kim MS, Park SJ, Park ES, Choi KS, Kim YS, et al. Novel temperature-triggered liposome with high stability: formulation, in vitro evaluation and in vivo study combined with high-intensity focused ultrasound (HIFU). *J Control Release*. 2013 Sep 28;170(3):373-9. doi: 10.1016/j.jconrel.2013.06.003.
44. Jain M, Kumar S, Aswal VK, Al-Ghamdi A, Kailasa SK, Malek NI. Amino acid induced self-assembled vesicles of choline oleate: pH responsive nano-carriers for targeted and localized delivery of doxorubicin for breast cancer. *J Mol Liquids*. 2022 Aug 15;360:119517. doi: 10.1016/j.molliq.2022.119517.
45. Palanikumar L, Al-Hosani S, Kalmouni M, Nguyen VP, Ali L, Pasricha R, et al. pH-responsive high stability polymeric nanoparticles for targeted delivery of anti-cancer therapeutics. *Commun Biol*. 2020 Mar 3;3(1):95. doi: 10.1038/s42003-020-0817-4.
46. Wen S, Liu H, Cai H, Shen M, Shi X. Targeted and pH-responsive delivery of doxorubicin to cancer cells using multifunctional dendrimer-modified multi-walled carbon nanotubes. *Adv Healthc Mater*. 2013 Sep;2(9):1267-76. doi: 10.1002/adhm.201200389.
47. Lee H, Park H, Noh GJ, Lee ES. pH-responsive hyaluronate-anchored extracellular vesicles to promote tumor-targeted drug delivery. *Carbohydr Polym*. 2018 Dec 15;202:323-33. doi: 10.1016/j.carbpol.2018.08.141.
48. Fang Y, Xue J, Ke L, Liu Y, Shi K. Polymeric lipid vesicles with pH-responsive turning on-off membrane for programmed delivery of insulin in GI tract. *Drug Deliv*. 2016 Nov;23(9):3582-93. doi: 10.1080/10717544.2016.1212440.
49. Tanner EEL, Curreri AM, Balkaran JPR, Selig-Wober NC, Yang AB, Kendig C, et al. Design principles of ionic liquids for transdermal drug delivery. *Adv Mater*. 2019 Jul;31(27):e1901103. doi: 10.1002/adma.201901103.
50. Jorge LR, Harada LK, Silva EC, Campos WF, Moreli FC, Shimamoto G, et al. Non-invasive transdermal delivery of human insulin using ionic liquids: in vitro studies. *Front Pharmacol*. 2020 Apr 23;11:243. doi: 10.3389/fphar.2020.00243.
51. Voges M, Prikhodko IV, Prill S, Hübner M, Sadowski G, Held C. Influence of pH value and ionic liquids on the solubility of L-alanine and L-glutamic acid in aqueous solutions at 30 °C. *J Chem Eng Data*. 2017 Jan;9: 52-61. doi: 10.1021/acs.jced.6b00367.
52. Klein R, Müller E, Kraus B, Brunner G, Estrine B, Touraud D, et al. Biodegradability and cytotoxicity of choline soaps on human cell lines: Effects of chain length and the cation. *RSC Adv*. 2013 Oct; 3: 23347-54. doi: 10.1039/c3ra42812e.
53. Klein R, Touraud D, Kunz W. Choline carboxylate surfactants: Biocompatible and highly soluble in water. *Green Chem*. 2008 Feb;10:433-5. doi: 10.1039/b718466b.
54. Ouellette RJ, Rawn JD. Amino Acids, Peptides and Proteins. *Princ Org Chem*. 2015 Jan; 5 :371-96. doi: 10.1002/9783527631827.
55. Shah MUH, Sivapragasam M, Moniruzzaman M, Talukderet RM, Suzana Y, Goto M. Aggregation behavior and antimicrobial activity of a micellar system of binary ionic liquids. *J Mol Liq*. 2018 Sep;266:568-76. doi: 10.1007/s00396-008-1976-x.
56. Forde BG, Lea PJ. Glutamate in plants: metabolism, regulation and signalling. *J Exp Bot*. 2007 Jul; 58: 2339-58. doi: 10.1093/jxb/erm121.
57. Hashem AH, Hasanin M, Kamel P, Dacrory S. A new approach for antimicrobial and antiviral activities of biocompatible nanocomposite based on cellulose, amino acid and graphene oxide. *Colloids Surfaces B Biointerfaces*. 2022 Oct;209:86-9. doi: 10.1016/j.colsurfb.2021.112172.
58. Wang C, Zhang Z, Chen B, Gu L, Li Y, Yu S. Design and evaluation of galactosylated chitosan/graphene oxide nanoparticles as a drug delivery system. *J Colloid Interface Sci*. 2018 Apr 15; 516: 332-41. doi: 10.1016/j.jcis.2018.01.073.
59. Zainal-Abidin MH, Hayyan M, Ngoh GC, Wong WF. Doxorubicin loading on functional graphene as a promising nanocarrier using ternary deep eutectic solvent systems. *ACS Omega*. 2020 Jan 15;5:1656-68. doi: 10.1021/acsomega.9b03709.
60. Hasanin M, Taha NF, Abdou AR, Emara LH. Green decoration of graphene oxide Nano sheets with gelatin and gum Arabic for targeted delivery of doxorubicin. *Bio-technol Reports*. 2022 Jun; 34: 722. doi: 10.1016/j.btre.2022.e00722.
61. Hernandez EP, Lazarin-Bidóia D, Bini RD, Nakamura CV, Cotica LF, Lautenschlager SOS. Doxorubicin-loaded iron oxide nanoparticles induce oxidative stress and cell cycle arrest in breast cancer cells. *Antioxidants*. 2023 Jan; 12: 237. doi: 10.3390/antiox12020237.
62. Żelechowska-Matysiak K, Salvanou EA, Bouziotis P, Budlewski T, Bilewicz A, Majkowska-Pilip A. Improvement of the effectiveness of HER2+ cancer therapy by use of doxorubicin and trastuzumab modified radioactive gold nanoparticles. *Mol Pharm*. 2023 Sep; 20: 4676-86. doi: 10.1021/acs.molpharmaceut.3c00414.
63. CN-114525269-A - Method for immobilizing laccase based on covalent bonding of polyethylene glycol and superparamagnetic iron oxide nanoparticles [Internet]. [Cited: 1-Avg-2024]. Available from: <https://portal.unifiedpatents.com/patents/patent/CN-114525269-A>.
64. RU-2808909-C1 - Method of combined therapy for connective tissue sarcoma m-1 in rats using a conjugate of dipropoxybacteriopurpurin with doxorubicin [Internet]. [Cited: 1-Avg-2024]. Available from: <https://portal.unifiedpatents.com/patents/patent/RU-2808909-C1>.
65. CN-115444810-B - Preparation method of doxorubicin-loaded nanoparticle composite temperature-sensitive gel. [Internet]. [Cited: 1-Avg-2024]. Available from: <https://portal.unifiedpatents.com/patents/patent/CN-115444810-B>.
66. Fu Z, Xiang J. Aptamer-functionalized nanoparticles in targeted delivery and cancer therapy. *Int J Mol Sci*. 2020 Dec; 21:1-39.
67. RU-2794798-C1 - pharmaceutical composition containing doxorubicin as part of phospholipid nanoparticles using selective DNA aptamer molecules for targeted transport to tumor cells [Internet]. [Cited: 1-Avg-2024]. Available from: <https://portal.unifiedpatents.com/patents/patent/RU-2794798-C1>.

68. US5672662A. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications [Internet]. [Cited: 1-Avg-2024]. Available from: <https://patents.google.com/patent/US5672662A/en>.
69. Chopra H, Bibi S, Kumar S, Khan MS, Kumar P, Singh I. Preparation and evaluation of chitosan/pva based hydrogel films loaded with honey for wound healing application. *Gels*. 2022 Feb 11;8:111-8. doi: 10.3390/gels8020111.
70. Chopra H, Mishra AK, Singh I, Mohanta YK, Sharma R, Bin Emran T, et al. Nano-chitosan: A novel material for glioblastoma treatment. *Int J Surg*. 2022 May; 104: 106713. doi: 10.1155/2022/4155729.
71. Chopra H, Bibi S, Singh I, Hasan MM, Khan MS, Yousafi Q, et al. Green metallic nanoparticles: biosynthesis to applications. *Front Bioeng Biotechnol*. 2022 Apr 6; 10: 548. doi: 10.3389/fbioe.2022.874742.
72. Bakshi IS, Chopra H, Sharma M, Kaushik D, Pahwa R, Haryanto. Herbal bioactives for wound healing application. *Herb Bioact Drug Deliv Syst*. 2022 Jan: 259–82. doi: 10.1016/B978-0-12-824385-5.00003-0.
73. Bhattacharya T, Soares GABE, Chopra H, Rahman MM, Hasan Z, Swain SS, et al. Applications of phyto-nanotechnology for the treatment of neurodegenerative disorders. *Materials*. 2022; 15:1–32. doi: 10.3390%2Fma15030804.
74. Walia V, Kaushik D, Mittal V, Kumar K, Verma R, Parashar J, et al. Delineation of neuroprotective effects and possible benefits of antioxidants therapy for the treatment of Alzheimer's diseases by targeting mitochondrial-derived reactive oxygen species: Bench to Bedside. *Mol Neurobiol*. 2022; 59: 657–80. doi: 10.1007/s12035-021-02617-1.
75. Chopra H, Gandhi S, Gautam RK, Kamal MK. Bacterial nanocellulose based wound dressings: current and future prospects. *Curr Pharm Des*. 2021; 28: 570–80. doi: 10.2174/1381612827666211021162828.
76. Saleem S, Bibi S, Yousafi Q, Hassan T, Khan MS, Hasan MM, et al. Identification of effective and nonpromiscuous antidiabetic drug molecules from penicillium species. *Evidence-Based Complement Altern Med*. 2022 Jun 8; 1–15. doi: 10.1155/2022/7040547.
77. Khalil MS, Shakeel M, Gulfam N, Ahmad SU, Aziz A, Ahmad J, et al. Fabrication of silver nanoparticles from ziziphus nummularia fruit extract: effect on hair growth rate and activity against selected bacterial and fungal strains. *J Nanomater*. 2022 June 25; 2022: 1–14. doi: 10.1155/2022/3164951.
78. Pandey P, Chopra H, Kaushik D, Verma R, Purohit D, Parashar J, et al. Multifunctional patented nanotherapeutics for cancer intervention: 2010-onwards. recent pat anticancer. *Drug Discov*. 2022;17: 38-52. doi: 10.2174/1574892817666220322085942.
79. Singla RK, Sai CS, Chopra H, Behzad S, Bansal H, Goyal R, et al. Natural products for the management of castration-resistant prostate cancer: special focus on nanoparticles based studies. *Front Cell Dev Biol*. 2021 Nov 5; 9: 1-15. doi: 10.3389/fcell.2021.745177.
80. Meel RV, Sulheim E, Shi Y, Kiessling F, Mulder WJM, Lammers T. Smart cancer nanomedicine. *Nat Nanotechnol*. Nov 2019; 14: 1007–17. doi: 10.1038/s41565-019-0567-y.